Consultant Urological Surgeon | Director Edinburgh Bladder Cancer Surgery @EdinSurg_BC | @Uroweb Bladder Cancer Guideline panels | Golfer. Views my own
Which is exactly why we at @IBCG_BladderCA [and @sitcancer] have maintained that TaHG should be classified as high risk.
Because the clinical outcomes, molecular biology, progression patterns, all point in the same direction.
High-grade biology matters more than arbitrary cutoffs; a TaHG tumor does not suddenly become biologically “intermediate risk” because it is 2.95 cm versus 3.02 cm
Classification is not semantics. Classification drives treatment. And treatment drives outcomes. @BladderCancerUS@WorldBladderCan
Great discussions here at the Masterclass on Muscle-invasive bladder cancer, April 16 & 17 in Amsterdam, the Netherlands.
It was a pleasure to reconnect with Prof. Prof Param Mariappan during the congress. #innovation#oncology#BladderEpiCheck
What could have been a turf war turned into something far more valuable! Our patients with #BladderCancer deserve better than siloed care after TMT. Shared surveillance and multidisciplinary counseling are the standard we should be holding ourselves to right now.
I know some of you were hoping for more fireworks at #EAU25 - May 17 might be your lucky day. 😏 @IBCG_BladderCA - @AmerUrological #BladderCancer Forum at #AUA26
@nehavapiwala Toine @ParamMariappan #EAU25 @AlisonBirtle@achoud72@Prof_Nick_James@VedangMurthy
After all the comments on EV209 (A phase 2 study of EVPx9 without cystectomy in the cCRs in MIBC patients), we decided to make a @Uromigos podcast on it and invite some of the voices @LauraBukavinaMD@AmandaNizamMD@DrTylerStewart ⚡️🌪️👉https://t.co/ra6aQt6Pv8